Phase 2, Phase 3 Recruiting Academic/Other
This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…
Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in Connecticut: - Yale University — New Haven, Connecticut
- Smilow Cancer Hospital Care Center-Trumbull — Trumbull, Connecticut
Phase 3 Recruiting Industry
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refract…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07276399
Sites in Connecticut: - Hartford Hospital — Hartford, Connecticut
- Yale Cancer Center — New Haven, Connecticut
Phase 3 Recruiting Industry
The goal of this study is to understand whether CRB-701, a targeted form of chemotherapy called an anti-body drug conjugate, will work as a treatment for oropharyngeal (throat, tonsil) cancer. In patients who have already received platinum…
Sponsor: Corbus Pharmaceuticals Inc.
NCT ID: NCT07768189
Sites in Connecticut: - Yale School of Medicine — Newhaven, Connecticut
Phase 3 Recruiting Industry
The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)
Sponsor: GlaxoSmithKline
NCT ID: NCT06256588
Sites in Connecticut: - GSK Investigational Site — Farmington, Connecticut
- GSK Investigational Site — New Haven, Connecticut
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is …
Sponsor: AVEO Pharmaceuticals, Inc.
NCT ID: NCT06064877
Sites in Connecticut: - Yale School of Medicine - Smilow Cancer Hospital — New Haven, Connecticut
Phase 2 Recruiting NIH
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04671667
Sites in Connecticut: - Smilow Cancer Center/Yale-New Haven Hospital — New Haven, Connecticut
- Yale University — New Haven, Connecticut
- Smilow Cancer Hospital Care Center-Trumbull — Trumbull, Connecticut
- Smilow Cancer Hospital Care Center - Waterford — Waterford, Connecticut
Phase 2 Recruiting NIH
This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06064097
Sites in Connecticut: - Connecticut Children's Medical Center — Hartford, Connecticut
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Connecticut: - Yale Cancer Center — New Haven, Connecticut
Phase 1, Phase 2 Recruiting Industry
This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy…
Sponsor: Avenzo Therapeutics, Inc.
NCT ID: NCT07038343
Sites in Connecticut: - Avenzo Therapeutics Recruiting Site — New Haven, Connecticut
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
Sponsor: Volastra Therapeutics, Inc.
NCT ID: NCT05902988
Sites in Connecticut: - Yale Cancer Center — New Haven, Connecticut
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of…
Sponsor: Gilead Sciences
NCT ID: NCT06657222
Sites in Connecticut: - Yale Cancer Center — New Haven, Connecticut
Phase 1, Phase 2 Recruiting Industry
Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors
Sponsor: Ensem Therapeutics
NCT ID: NCT06993844
Sites in Connecticut: - Yale University, Yale Cancer Center — New Haven, Connecticut
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 monotherapy in adult patients with s…
Sponsor: Alentis Therapeutics AG
NCT ID: NCT06747585
Sites in Connecticut: - Yale Comprehensive Cancer Center — New Haven, Connecticut
Phase 2 Recruiting Industry
This is a multicenter, multi-arm trial evaluating anti-tumor activity, safety, and immune infiltration of IO102-IO103 in combination with pembrolizumab KEYTRUDA® as neoadjuvant and post-surgery treatment. This proof-of-concept trial will i…
Sponsor: IO Biotech
NCT ID: NCT05280314
Sites in Connecticut: - Yale — New Haven, Connecticut
Phase 2 Recruiting Industry
This will be a multi-center, randomized, open-label, parallel-group study in adult patients with head and neck cancer.
Sponsor: VSPharmTech Co.,Ltd.
NCT ID: NCT06959082
Sites in Connecticut: - Yale Cancer Center — New Haven, Connecticut
Phase 2 Recruiting Academic/Other
This is a phase 2, pilot, randomized, open-label 3-arm study to assess the safety, tolerability, and efficacy of CUE-101 monotherapy, and CUE-101 in combination with pembrolizumab as neoadjuvant therapy in HLA-A\*0201-positive treatment na…
Sponsor: Yale University
NCT ID: NCT07172256
Sites in Connecticut: - Yale University — New Haven, Connecticut
Phase 2 Recruiting Academic/Other
This study is being done because both 5-azacytidine and nivolumab can influence the immune system's response to HPV-associated head and neck cancer, and we wish to evaluate whether taking 5-azacytidine will make HPV-associated head and nec…
Sponsor: Barbara Burtness
NCT ID: NCT05317000
Sites in Connecticut: - Yale University — New Haven, Connecticut
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Connecticut: - Exelixis Clinical Site #62 — New Haven, Connecticut
Phase 1 Recruiting Industry
The goal of this study is to evaluate the safety and effectiveness of EVOLVE104 in participants with advanced urothelial and squamous cell carcinomas who have previously taken standard treatment options, have declined or have been ineligib…
Sponsor: EvolveImmune United, Inc
NCT ID: NCT07217171
Sites in Connecticut: - Yale University Cancer Center — New Haven, Connecticut
Phase 1 Recruiting Industry
Adcendo ApS is conducting a phase 1 study of an investigational drug called ADCE-T02 (previously known as AMT-754), a tissue factor targeted antibody-drug conjugate which may be used in the future as a possible treatment for advanced solid…
Sponsor: Adcendo ApS
NCT ID: NCT06597721
Sites in Connecticut: - Yale University Cancer Center — New Haven, Connecticut
Phase 1 Recruiting Industry
The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known Ly6E expr…
Sponsor: EMD Serono Research & Development Institute, Inc.
NCT ID: NCT07360314
Sites in Connecticut: - Yale University - Yale University School of Medicine — New Haven, Connecticut
Phase 1 Recruiting Industry
This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.
Sponsor: Kivu Bioscience Inc.
NCT ID: NCT07229313
Sites in Connecticut: - Kivu Trial Site — New Have, Connecticut
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Connecticut: - Massive Bio SYNERGY-AI site — Hartford, Connecticut
- Massive Bio SYNERGY-AI site — Norwalk, Connecticut